Methods and compositions for monitoring and risk prediction in cardiorenal syndrome
AssigneeAlere International
InventorsGunars Valkirs, Paul H. McPherson
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.
Claims12
A method of assigning a risk of an adverse outcome to a patient suffering from heart failure, comprising:
- performing an assay method that detects NGAL (neutrophil gelatinase-associated lipocalin) on a body fluid sample obtained from said patient, thereby providing an NGAL assay result;
- comparing said NGAL assay result to a baseline NGAL result;
- and
- relating the NGAL assay result to the patient's risk by assigning an increased likelihood of an adverse outcome to said patient when said NGAL assay result is greater than said baseline NGAL result, relative to a risk assigned when said NGAL assay result is less than said baseline NGAL result, or by assigning a decreased likelihood of an adverse outcome to said patient when said NGAL assay result is less than said baseline NGAL result, relative to a risk assigned when said NGAL assay result is greater than said baseline NGAL result.
Dependencies are inferred from the claim text.